about
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanomaThe somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomasDiagnostic and pathogenetic role of café-au-lait macules in nevoid basal cell carcinoma syndrome.Multiphoton laser tomography and fluorescence lifetime imaging of melanoma: morphologic features and quantitative data for sensitive and specific non-invasive diagnostics.Diagnosis of BCC by multiphoton laser tomography.Multiphoton laser tomography and fluorescence lifetime imaging of basal cell carcinoma: morphologic features for non-invasive diagnostics.Muir-Torre syndrome.Is confocal microscopy a valuable tool in diagnosing nodular lesions? A study of 140 cases.Proteomic analysis of PTCH1+/- fibroblast lysate and conditioned culture media isolated from the skin of healthy subjects and nevoid basal cell carcinoma syndrome patients.Clinico-pathological and biomolecular findings in Italian patients with multiple cutaneous neurofibromas.Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer.Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report.Cancer-associated genodermatoses: skin neoplasms as clues to hereditary tumor syndromes.Fluorescence in-situ hybridization and dermoscopy in the assessment of controversial melanocytic tumors.Skeletal and cranio-facial signs in Gorlin syndrome from ancient Egypt to the modern age: sphenoid asymmetry in a patient with a novel PTCH1 mutation.Brooke-Spiegler syndrome tumor spectrum beyond the skin: a patient carrying germline R936X CYLD mutation and a somatic CYLD mutation in Brenner tumor.Stem cell properties in cell cultures from different stage of melanoma progression.Epidemiology of colorectal cancer: the 21-year experience of a specialised registry.High magnification digital dermoscopy of basal cell carcinoma: a single-centre study on 400 cases.Leser-Trélat syndrome in patients affected by six multiple metachronous primitive cancers.Quantitative evaluation of healthy epidermis by means of multiphoton microscopy and fluorescence lifetime imaging microscopy.Italian Euromelanoma Day Screening Campaign (2005-2007) and the planning of melanoma screening strategies.Ameloblastoma: a neglected criterion for nevoid basal cell carcinoma (Gorlin) syndrome.Clinical utility gene card for: Gorlin syndrome--update 2013Microsatellite instability and mismatch repair protein expression in sebaceous tumors, keratocanthoma, and basal cell carcinomas with sebaceous differentiation in Muir-Torre syndrome.Can noninvasive imaging tools potentially predict the risk of ulceration in invasive melanomas showing blue and black colors?Microsatellite instability and colorectal cancer prognosis.Relationship between MUC5AC and altered expression of MLH1 protein in mucinous and non-mucinous colorectal carcinomas.Giuseppe Moscati (1880-1927): a holistic approach to medicine.Variegated dermoscopy of in situ melanoma.The dermoscopic variability of pigment network in melanoma in situ.Reticular grey-blue areas of regression as a dermoscopic marker of melanoma in situ.Malignant and benign tumors associated with multiple primary melanomas: just the starting block for the involvement of MITF, PTEN and CDKN2A in multiple cancerogenesis?Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients.Brooke-Spiegler syndrome: report of two cases not associated with a mutation in the CYLD and PTCH tumor-suppressor genes.Malignant melanoma in patients with hereditary nonpolyposis colorectal cancer.BRAF mutations in multiple sebaceous hyperplasias of patients belonging to MYH-associated polyposis pedigrees.Immunohistochemical expression of MYH protein can be used to identify patients with MYH-associated polyposis.Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes.
P50
Q27851927-CDB3A27F-89E4-4064-BA9E-5843AABC8B4EQ27852112-0E86FD12-FFC5-4BC6-BB38-B58D558DBA18Q28250809-C7CA6752-D68E-44BC-91FF-85A02D203717Q30460683-163D746D-2B6A-4029-92C2-A8D676ED26FAQ30660085-F7714A46-6B89-4549-A399-79A2FBF1C6EAQ34331040-6697CBB6-0B1F-485F-839A-F8AB1FC1DF7AQ34375394-283ED404-CAD7-487E-AB91-411594388D5BQ34471931-35342846-DE82-4CF4-A99E-7BCA1FE79AECQ34572022-3404DE60-CC39-459A-A46F-73AAD23B03A3Q35076065-11C1A0DB-ED05-40F8-90AB-0E0DE4971C42Q35428487-33B86156-7E95-403A-AAED-8C50835CB2BBQ36696628-C8E873BD-AB6C-48BC-B9FC-B2DC4EB9844EQ37316281-679F95F5-80DA-462F-B1E0-F65E63688AFEQ38028646-30224043-0635-4308-9298-BB041A56B6BCQ38146733-36DBC7D8-AD4E-40FF-929C-92093DD9E18CQ39173903-D1F857B3-0243-4014-A19E-A252A836E607Q39246743-BCE52B0B-612A-4122-B998-3AA6CF1EAEF8Q39413556-7355963F-62C2-4D3C-B7F2-CA6BBB5C974AQ40146719-EF53D032-42B1-4E1A-9260-D567ACABADEDQ40180952-25510F05-FFF3-4E12-AB25-5487D2835BC6Q41899354-E51534C9-361C-4C32-8781-94FBF15001D4Q42487184-50EEF9F6-0797-45AF-9E8D-C64D90619946Q42496047-46432D3E-A1BB-407D-8781-DD637480D37FQ42505959-94FCA301-3D84-4A53-B30A-38B0076C9D16Q42519992-6D0547FA-8813-425C-A44F-B092C794BBEEQ42520495-C0CC4924-2716-45BB-9409-C2390F68849BQ43498106-EC6B3058-06EC-4976-9C63-7C6D6BA9DD7CQ46831092-44C3119D-D379-4A21-9A16-E394CAE4AA05Q47236302-125E6155-DEB4-45AB-928D-85E4694DFA72Q48084424-1A72FFF8-0730-420A-9CD9-6D44C54C1F27Q50246133-EAA32E52-F1F8-4395-9DE5-51AF5804B068Q50250657-188D6693-E469-4A9A-A5D8-22C044E7A5AFQ50445696-FE9B1C1A-3AC5-4F1F-B792-96834D583929Q50876968-DD520BD5-601F-40DD-88E4-C742FC6296A5Q53200165-6BF90B01-55FD-4734-A9F0-4BDD1F3B1955Q53206549-1F2B6BA3-22BB-4B54-9138-AF476D085CA6Q53321594-90E77307-66C4-44CD-B3FE-764E5DDA43FFQ54447420-BE38FFF6-2E0A-4ACE-8515-CAF5BAA5A64DQ54458298-2EB90780-AACA-450A-A613-05D45F6DBCC0Q54478476-D04E222D-4597-44EE-86C5-721131459735
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Giovanni Ponti
@ast
Giovanni Ponti
@en
Giovanni Ponti
@es
Giovanni Ponti
@nl
Giovanni Ponti
@sl
type
label
Giovanni Ponti
@ast
Giovanni Ponti
@en
Giovanni Ponti
@es
Giovanni Ponti
@nl
Giovanni Ponti
@sl
prefLabel
Giovanni Ponti
@ast
Giovanni Ponti
@en
Giovanni Ponti
@es
Giovanni Ponti
@nl
Giovanni Ponti
@sl
P1053
A-5565-2012
P106
P1153
7005854235
P21
P214
79149842032702842390
P31
P3829
P496
0000-0002-1971-7306
P734
P735
P7859
viaf-79149842032702842390